2024
Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Shah A, Fox S, Wang A. Long‐Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER‐OLE Study. Journal Of The American Heart Association 2024, 13: e030607. PMID: 38591260, PMCID: PMC11262496, DOI: 10.1161/jaha.123.030607.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire–Overall Summary scoreSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientHypertrophic cardiomyopathyNew York Heart Association class improvementLeft ventricular outflow tract gradientTreatment-emergent adverse eventsSerum NT-proBNP levelsLeft ventricular ejection fractionEffect of mavacamtenIndividual dose titrationNT-proBNP levelsVentricular ejection fractionSerum NT-proBNPSummary scoreLong-term safetyLonger-term treatmentDose titrationEjection fractionNT-proBNPB-blockersReduced doseAdverse eventsInterim resultsPREDICTORS OF ADVERSE LONG-TERM OUTCOME AFTER SEPTAL REDUCTION THERAPIES IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY : INSIGHTS FROM THE SHARE REGISTRY
Maurizi N, Antiochos P, Owens A, Lakdawala N, Saberi S, Russell M, Lin K, De Feria Alsina A, Reza N, Stendahl J, Abrams D, Semsarian C, Lampert R, Parikh V, Wheeler M, Ashley E, Michels M, Rossano J, Ryan T, Ingles J, Ware J, Ho C, Helms A, Day S, Olivotto I. PREDICTORS OF ADVERSE LONG-TERM OUTCOME AFTER SEPTAL REDUCTION THERAPIES IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY : INSIGHTS FROM THE SHARE REGISTRY. Journal Of The American College Of Cardiology 2024, 83: 353. DOI: 10.1016/s0735-1097(24)02343-x.Peer-Reviewed Original ResearchPredictor of adverse long-term outcomesObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathy
2023
Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry
Alaiwi S, Roston T, Marstrand P, Claggett B, Parikh V, Helms A, Ingles J, Lampert R, Lakdawala N, Michels M, Owens A, Rossano J, Saberi S, Abrams D, Ashley E, Semsarian C, Stendahl J, Ware J, Miller E, Ryan T, Russell M, Day S, Olivotto I, Vissing C, Ho C. Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry. Circulation 2023, 148: 394-404. PMID: 37226762, PMCID: PMC10373850, DOI: 10.1161/circulationaha.122.062517.Peer-Reviewed Original ResearchConceptsLeft ventricular systolic dysfunctionHypertrophic cardiomyopathyMedian ageHCM diagnosisVentricular assist device implantationCox proportional hazards modelComposite of deathVentricular systolic dysfunctionAssist device implantationVentricular ejection fractionProportional hazards modelCardiac transplantationSystolic dysfunctionEjection fractionHCM cohortPediatric cohortDevice implantationPoor outcomeSubsequent prognosisEchocardiographic reportsHazards modelPatientsAdult cohortPrognosisCohortLONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY
Masri A, Lester S, Stendahl J, Hegde S, Sehnert A, Balaratnam G, Fox S, Wang A. LONG-TERM SAFETY AND EFFICACY OF MAVACAMTEN IN PATIENTS (PTS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM): UPDATED RESULTS FROM THE PIONEER-OLE STUDY. Journal Of The American College Of Cardiology 2023, 81: 346. DOI: 10.1016/s0735-1097(23)00790-8.Peer-Reviewed Original ResearchHypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyPatients